Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 9MW2821 plus toripalimab versus standard platinum-gemcitabine chemotherapy as first-line treatment for locally advanced or metastatic urothelial carcinoma
CTR20242828Phase 3Active
- Sponsor
- Mabwell
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bulumtatug fuvedotin and toripalimab in transitional cell carcinoma (TCC) (2 arms), sponsored by Mabwell. Primary endpoints: Blinded independent central review progression-free survival and Overall survival. Started Aug 2024; status: active.
02
Drugs
bulumtatug fuvedotintoripalimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20242828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242828.